HomeCompareSPVNF vs JNJ

SPVNF vs JNJ: Dividend Comparison 2026

SPVNF yields 37037.04% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPVNF wins by $2.4065325904961905e+22M in total portfolio value
10 years
SPVNF
SPVNF
● Live price
37037.04%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.4065325904961905e+22M
Annual income
$23,938,182,827,095,612,000,000,000,000.00
Full SPVNF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SPVNF vs JNJ

📍 SPVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPVNFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPVNF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPVNF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPVNF
Annual income on $10K today (after 15% tax)
$3,148,148.15/yr
After 10yr DRIP, annual income (after tax)
$20,347,455,403,031,270,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SPVNF beats the other by $20,347,455,403,031,270,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPVNF + JNJ for your $10,000?

SPVNF: 50%JNJ: 50%
100% JNJ50/50100% SPVNF
Portfolio after 10yr
$1.2032662952480952e+22M
Annual income
$11,969,091,413,547,806,000,000,000,000.00/yr
Blended yield
99.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SPVNF
No analyst data
Altman Z
-94.6
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPVNF buys
0
JNJ buys
0
No recent congressional trades found for SPVNF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPVNFJNJ
Forward yield37037.04%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$2.4065325904961905e+22M$30.3K
Annual income after 10y$23,938,182,827,095,612,000,000,000,000.00$4,689.40
Total dividends collected$2.4056969570736264e+22M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPVNF vs JNJ ($10,000, DRIP)

YearSPVNF PortfolioSPVNF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$3,714,404$3,703,703.70$10,592$272.30+$3.70MSPVNF
2$1,289,680,090$1,285,705,677.99$11,289$357.73+$1289.67MSPVNF
3$418,586,082,750$417,206,125,053.69$12,123$472.89+$418586.07MSPVNF
4$127,000,083,643,664$126,552,196,535,121.55$13,141$629.86+$127000083.63MSPVNF
5$36,020,244,067,789,990$35,884,353,978,291,260.00$14,408$846.81+$36020244067.78MSPVNF
6$9,550,369,884,101,736,000$9,511,828,222,949,202,000.00$16,021$1,151.60+$9550369884101.72MSPVNF
7$2,367,187,305,717,691,300,000$2,356,968,409,941,702,600,000.00$18,122$1,588.22+$2367187305717691.50MSPVNF
8$548,520,032,501,626,100,000,000$545,987,142,084,508,200,000,000.00$20,930$2,228.20+$548520032501626112.00MSPVNF
9$118,825,306,417,094,130,000,000,000$118,238,389,982,317,400,000,000,000.00$24,792$3,191.91+$118825306417094131712.00MSPVNF
10$24,065,325,904,961,905,000,000,000,000$23,938,182,827,095,612,000,000,000,000.00$30,274$4,689.40+$2.4065325904961905e+22MSPVNF

SPVNF vs JNJ: Complete Analysis 2026

SPVNFStock

Spectra7 Microsystems Inc. operates as an analog semiconductor company in Canada and China. The company offers virtual reality (VR) products, including VR7050 to enable lightweight and ultra-thin active interconnects for gesture recognition and motion control backhaul; augmented reality (AR) -Connect, an integrated cable, connector, and embedded chipset product line for AR vision systems and wearable computing devices; and DreamWeVR to support high-bandwidth, near-zero latency VR head-mounted displays, and AR glasses. It also provides GaugeChanger that allows copper to extend much longer lengths without the cost and power penalty of optics that are used in data centers; and USB 3.2 consumer interconnects for use in ultra-thin laptops, tablets, mobile devices, solid-state disks, and wearable computing devices. Spectra7 Microsystems Inc. is headquartered in San Jose, California.

Full SPVNF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SPVNF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPVNF vs SCHDSPVNF vs JEPISPVNF vs OSPVNF vs KOSPVNF vs MAINSPVNF vs ABBVSPVNF vs MRKSPVNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.